Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Retained Earnings (2018 - 2025)

Historic Retained Earnings for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to -$34.4 million.

  • China SXT Pharmaceuticals' Retained Earnings fell 3476.45% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.4 million, marking a year-over-year decrease of 3476.45%. This contributed to the annual value of -$28.0 million for FY2025, which is 1336.88% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Retained Earnings of -$34.4 million as of Q3 2025, which was down 3476.45% from -$28.0 million recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Retained Earnings peaked at -$10.0 million during Q1 2021, and registered a low of -$34.4 million during Q3 2025.
  • Its 5-year average for Retained Earnings is -$22.1 million, with a median of -$23.2 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 12401.83% in 2021, then soared by 1850.91% in 2024.
  • Quarter analysis of 5 years shows China SXT Pharmaceuticals' Retained Earnings stood at -$13.0 million in 2021, then crashed by 31.73% to -$17.2 million in 2022, then tumbled by 82.21% to -$31.3 million in 2023, then increased by 18.51% to -$25.5 million in 2024, then crashed by 34.76% to -$34.4 million in 2025.
  • Its Retained Earnings was -$34.4 million in Q3 2025, compared to -$28.0 million in Q1 2025 and -$25.5 million in Q3 2024.